



3800 Gateway Centre Boulevard • Suite 308 • Morrisville, NC 27560 • (919) 465-2236 • Fax (919) 465-0153

SICEL CONTACT

Michael D. Riddle, President/CEO

(919)-465-2236 Ext. 259

www.siceltech.com

FOR IMMEDIATE RELEASE

August 29, 2006

Florida Cancer Centers First to Implement Sicel's DVS^R Implantable Radiation Sensor in the Treatment of Breast and Prostate Cancer

Raleigh NC (August 29, 2006) – Sicel Technologies, Inc. announced today that physicians at Boca Raton Community Hospital's Lynn Cancer Institute and Melbourne Internal Medical Associates (MIMA) Cancer Center are the first to incorporate the Company's DVS[®] (Dose Verification System) into their treatment protocols. DVS[®] is the first permanently implantable, wireless, telemetric radiation sensor for human use to be commercially available in the United States. Using the hand-held reader, physicians are able to determine after each treatment session the actual dose of radiation being delivered to the tumor and normal tissue.

“Both Lynn Cancer Institute and MIMA have a history of providing the best care for their cancer patients by being among the first centers to adopt cutting edge technologies,” said Michael Riddle, President & CEO of Sicel Technologies, Inc. “We are extremely pleased to have two such prestigious institutions as our first users in the United States.”

The Company has clearance to market DVS for use in an estimated 450,000 breast and prostate cancer patients in the US, with the potential for its use in an additional 500,000 European patients.

Commenting on the use of DVS, Tim Williams, MD, Chair of the Radiation Oncology Department at Lynn Regional Cancer Center said, “Radiation oncologists will now know with certainty that a patient is receiving the correct dose of radiation. This is just one example of our hospital's commitment to staying on the edge of technology and investing in what is best for the patient.”

In commenting on the acquisition of DVS for MIMA, Dr Joseph Ting, Chief Medical Physicist said, “We are pleased to be among the first centers offering this unique technology. DVS is needed to gain maximum benefit from modern radiation therapy treatments which aim to deliver high precision radiation doses to improve cancer cure.”

ABOUT LYNN CANCER INSTITUTE

The Lynn Cancer Institute, formerly known as Lynn Regional Cancer Center, is a multi-site practice owned by Boca Raton Community Hospital. It has been in operation for 28 years and has developed into one of the largest comprehensive cancer centers in Florida. A planned new 90,000 square-foot cancer center facility is slated to open in 2008. For further information, visit www.brch.com.

ABOUT MELBOURNE INTERNAL MEDICINE ASSOCIATES (MIMA)

MIMA is an independent, physician-owned multispecialty group offering patients comprehensive medical care throughout Brevard County, Florida. Comprised of over 100 physicians representing 23 medical specialties, MIMA's board-certified physicians provide high-quality medical care at 15 locations on Florida's Space Coast. The MIMA Cancer Center's Department of Radiation Oncology treats 80-90 patients per day. For further information, visit www.mima.com.

Sicel Technologies Inc. is a privately owned company with 31 employees headquartered in Morrisville, North Carolina. The Company was established in 1999 to develop a miniaturized, implantable device utilizing multiple sensors in a closed loop telemetry system. The Company's efforts have been focused in the oncology market segment to develop products that can continuously monitor the changes within tumors of patients undergoing radiation and chemotherapy. The implantable Dose Verification System or DVS^R was developed utilizing technology licensed from North Carolina State University.

Forward-Looking Statements

Statements contained in this release, which are not historical facts, may be considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and the current economic environment.

We caution the reader that such forward-looking statements are not guarantees of future performance. Unknown risk, uncertainties as well as other uncontrollable or unknown factors could cause actual results to materially differ from the results, performance or expectations expressed or implied by such forward-looking statements.

END